Top Markets
Coin of the day
Kolon TissueGene, Inc. Kolon TissueGene, Inc.

Kolon TissueGene, Inc.

950160
Rank in Stocks #9085
Kolon TissueGene, Inc. is a biopharmaceutical firm specializing in the... Kolon TissueGene, Inc. is a biopharmaceutical firm specializing in the advancement of clinical-stage cell-based treatments for osteoarthritis. Its flagship offering is TG-C, a proprietary platform technology that integrates allogeneic primary cells with genetically engineered counterparts. Established by Kwan H. Lee on June 9, 1999, the enterprise maintains its corporate headquarters in Rockville, Maryland.
Share Price
$12.94
Last synced: 2026-08-28
Market Cap
$1.10B
Change (1 day)
-0.16%
Change (1 year)
-51.50%
Country
US
Trade Kolon TissueGene, Inc. (950160)

Category

Earnings for Kolon TissueGene, Inc. (950160)
Earnings in 2026 TTM: 0
According to Kolon TissueGene, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Kolon TissueGene, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH